Literature DB >> 20362334

CD5+ B-cell lymphoproliferative disorders: Beyond chronic lymphocytic leukemia and mantle cell lymphoma.

Dragan Jevremovic1, Roxana S Dronca, William G Morice, Ellen D McPhail, Paul J Kurtin, Clive S Zent, Curtis A Hanson.   

Abstract

CD5 positivity in B-cell lymphoproliferative disorders (LPD) is usually considered characteristic of either chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). However, other neoplastic B-LPDs may express CD5, albeit infrequently. In this study we have reviewed the tissue pathology of CD5+ B-LPDs that do not fulfill diagnostic criteria for CLL or MCL on flow cytometric studies of peripheral blood or bone marrow. Our results indicate that although CD5 positivity is most commonly associated with CLL and MCL, a significant minority of cases do not fall into these two categories. Phenotypically unusual CLL, marginal zone lymphoma and lymphoplasmacytic lymphoma were the most common diagnoses in this group of patients. Applying strict flow cytometry criteria, using genetic studies, and deferring to a lymph node/tissue diagnosis in non-classical cases are critical for accurate diagnosis and classification of CD5+ B-cell LPD. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20362334     DOI: 10.1016/j.leukres.2010.03.020

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  7 in total

1.  CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases.

Authors:  Yu Li; Shimin Hu; Zhuang Zuo; Ming Hong; Pei Lin; Shaoying Li; Sergej Konoplev; Zhen Wang; Joseph D Khoury; Ken H Young; L Jeffrey Medeiros; C Cameron Yin
Journal:  Mod Pathol       Date:  2015-03-06       Impact factor: 7.842

Review 2.  Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach.

Authors:  Clive S Zent; Neil E Kay
Journal:  Leuk Lymphoma       Date:  2011-06-08

3.  Aberrant Immunophenotypic Expression of CD5 in a Case of B Acute Lymphoblastic Leukemia: A Case Report.

Authors:  Deepti Mutreja; Hara Prasad Pati; Divya Bansal; Rahul Kumar Sharma; Sonal Jain
Journal:  Indian J Hematol Blood Transfus       Date:  2014-02-18       Impact factor: 0.900

4.  CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity.

Authors:  Roxana S Dronca; Dragan Jevremovic; Curtis A Hanson; Kari G Rabe; Tait D Shanafelt; William G Morice; Timothy G Call; Neil E Kay; Charles S Collins; Susan M Schwager; Susan L Slager; Clive S Zent
Journal:  Cytometry B Clin Cytom       Date:  2010       Impact factor: 3.058

5.  Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders.

Authors:  Shuhua Yi; Zengjun Li; Dehui Zou; Wenjie Xiong; Heng Li; Rui Cui; Chengwen Li; Yuting Yan; Wei Liu; Rui Lv; Zhen Yu; Weiwei Chen; Yan Xu; Gang An; Huijun Wang; Kun Ru; Tao Cheng; Jianxiang Wang; Lugui Qiu
Journal:  Oncotarget       Date:  2017-12-15

6.  Pseudo liposarcomatous plasma cells in a patient with liposarcoma and lymphoplasmacytic lymphoma.

Authors:  Adrian Schmidt; Antoinette Monn; Elisabeth Schmidt-Weiss; Mathias Schmid; Beatrix Boesch
Journal:  Clin Case Rep       Date:  2018-02-06

7.  Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.

Authors:  Zijun Y Xu-Monette; Meifeng Tu; Kausar J Jabbar; Xin Cao; Alexandar Tzankov; Carol Visco; Lalitha Nagarajan; Qingqing Cai; Santiago Montes-Moreno; Yuji An; Karen Dybkaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Xiaoying Zhao; Michael B Møller; John P Farnen; Jane N Winter; Miguel A Piris; Roberto N Miranda; L Jeffrey Medeiros; Ken H Young
Journal:  Oncotarget       Date:  2015-03-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.